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AbstrACt
Introduction Young people aged 16 to 24 have the 
highest prevalence of genital chlamydia and gonorrhoea 
compared with other age groups and re- infection rates 
following treatment are high. Long- term adverse health 
effects include subfertility and ectopic pregnancy, 
particularly among those with repeated infections. We 
developed the safetxt intervention delivered by text 
message to reduce sexually transmitted infection (STI) 
by increasing partner notification, condom use and (STI) 
testing among young people in the UK.
Methods and analysis A single- blind randomised trial 
to reliably establish the effect of the safetxt intervention 
on chlamydia and gonorrhoea infection at 1 year. We will 
recruit 6250 people aged 16 to 24 years who have recently 
been diagnosed with chlamydia, gonorrhoea or non- specific 
urethritis from health services in the UK. Participants will be 
allocated to receive the safetxt intervention (text messages 
designed to promote safer sexual health behaviours) or 
to receive the control text messages (monthly messages 
asking participants about changes in contact details) by 
an automated remote online randomisation system. The 
primary outcome will be the cumulative incidence of 
chlamydia and gonorrhoea infection at 1 year assessed 
by nucleic acid amplification tests. Secondary outcomes 
include partner notification, correct treatment of infection, 
condom use and STI testing prior to sex with new partners.
Ethics and dissemination Ethics approval was obtained 
from NHS Health Research Authority - London – Riverside 
Research Ethics Committee (REC reference: 15/LO/1665) 
and the London School of Hygiene & Tropical Medicine. We 
will submit the results of the trial for publication in peer- 
reviewed journals.
trial registration number International Standard 
Randomised Controlled Trials Number: ISRCTN64390461. 
Registered on 17th March 2016. WHO trial registration 
data set available at: http:// apps. who. int/ trialsearch/ Trial2. 
aspx? TrialID= ISRCTN64390461.
trial protocol version 12, 19th July 2018.
IntroduCtIon
Younger people aged 16 to 24 bear the 
heaviest burden of sexually transmitted infec-
tions (STIs) such as chlamydia and gonor-
rhoea, and their long- term adverse health 
effects including ectopic pregnancy and 
subfertility.1 2 The risk of adverse health effects 
increases with repeated infections, and re- in-
fection rates following treatment are high: up 
strengths and limitations of this study
 ► The study design is a large randomised trial to as-
sess the effect of ‘safetxt’, a safer sex intervention 
delivered by text message, on objectively measured 
sexually transmitted infection (chlamydia and gon-
orrhoea) at 1 year.
 ► The use of an independent remote computer- 
based randomisation system linked to an auto-
mated message delivery system ensures allocation 
concealment.
 ► The secondary outcomes will assess the effect of 
the intervention on safer sex behaviours: partner no-
tification, condom use and testing before sex with a 
new partner.
 ► The process evaluation will explore which interven-
tion components are effective and has the potential 
to generate general principles to inform similar in-
terventions in the future.
 ► The inability to blind participants receiving a be-
havioural intervention is a limitation of the trial, 
which could introduce bias in the ascertainment of 
self- reported outcomes.
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Figure 1 Trial flow chart.
to 30% for chlamydia and 12% for gonorrhoea at 1 year.3 
Those with an STI are more likely to acquire further STIs 
and HIV, if exposed. There are marked inequalities in 
sexual health; STIs are positively associated with lower 
educational level4 and living in more deprived areas.1 5 6
Partner notification, condom use and STI testing can 
reduce infection and re- infection. There is some evidence 
that existing interventions delivered face- to- face that 
target condom use and/or STI testing may be effective, 
but they are limited in their reach or too costly for wide-
spread application.7 Existing interventions delivered via 
the media have high reach but their effects have yet to be 
established.8 Effective ways to increase partner notifica-
tion in specialist and primary care settings are needed.9 10
Mobile phones have the potential to provide effective, 
low cost health behaviour support.11 12 However, evidence 
for the effect of mobile phone support for safer sex 
behaviours such as condom use, partner notification and 
STI testing is equivocal.13–15 Interventions have targeted 
testing for STI,16–21 delaying resumption of sexual activity 
until 42 days after circumcision22 and condom use,17 18 23 24 
but none have aimed to increase partner notification. 
The effect of mobile phone based interventions on STI 
is not known.
In the UK, 99% of 16 to 24 year olds are mobile phone 
users (ONS, 2012) and mobile phone ownership is high 
across all socioeconomic groups. In research leading to 
this trial, it was demonstrated that interactive support 
via text message is particularly acceptable in the area of 
sexual health intervention.15 25 26
The safetxt trial builds on the successful intervention 
development work and pilot trial.15 26 27 To develop the 
intervention, we convened a working group including 
experts in health psychology, contraception research, 
contraception service provision, information technology 
and the development of interventions delivered by mobile 
phone. The intervention messages were developed based 
on: behaviour change theory, evidence- based behaviour 
change techniques, the content of effective face- to- 
face safer sex interventions, the factors known to influ-
ence safer sex behaviours, the views of 82 young people 
collected in focus groups and a questionnaire completed 
by 100 people aged 16 to 24.15 The theory and evidence- 
based intervention is designed to reduce STIs in young 
people by supporting them in telling a partner about an 
infection, using condoms and obtaining testing before 
unprotected sex with a new partner. In a qualitative study 
with young people, recipients reported that the tone, 
language, content and frequency of messages was appro-
priate.26 Messages reportedly increased knowledge and 
confidence in how to use condoms and reduced stigma 
enabling them to tell a partner about an STI. Sharing 
messages with their partner enabled participants to nego-
tiate condom use.
The pilot trial demonstrated that methods of recruit-
ment, randomisation, intervention delivery and follow- up 
were successful and that a full- scale randomised controlled 
trial of the safetxt intervention is feasible.27
objectives
The primary objective of this trial is to quantify the effects 
of the safetxt intervention compared with a control group 
receiving usual care and messages about trial participa-
tion on chlamydia or gonorrhoea infection at 1 year. 
Secondary objectives are to determine the effects of 
safetxt on partner notification and condom use at 4 weeks 
and on condom use and STI testing at 1 year. Which 
intervention components are effective will be explored 
by collecting data on the theoretical constructs on the 
pathway to behaviour change influenced by the interven-
tion components. The cost- effectiveness of the interven-
tion will be established.
MEthods And AnAlysIs
design and setting
Safetxt is a single- blind parallel group randomised superi-
ority trial with a 1:1 allocation ratio designed to establish 
the effects of a safer sex intervention delivered by text 
message on the cumulative incidence of chlamydia and 
gonorrhoea infection at 1 year. (See figure 1 for the trial 
flow chart).
Potential participants testing positive for chlamydia, 
gonorrhoea or diagnosed with non- specific urethritis 
(NSU) will be identified from UK STI testing services by 
research staff based at the service (a full list of partici-
pating services is available at http:// safetxt. lshtm. ac. uk/ 
participating- sites/). The intervention is delivered by text 
message in the community. Trial recruitment started on 
the 1st April 2016. Completion of follow- up and closure of 
the data set is planned for early spring 2020.
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Characteristics of participants
Inclusion criteria
Participants will be eligible if they are between 16 and 24 
years of age, own a personal mobile phone, are able to 
provide informed consent and who, in the 2 weeks prior 
to their recruitment, have either been diagnosed with 
chlamydia, gonorrhoea or NSU or have started treatment 
for chlamydia, gonorrhoea or NSU.
Exclusion criteria
Participants will be excluded if they are known to be a 
sexual partner of someone already recruited to the trial.
recruitment and consent
Research staff based at STI testing services will identify 
potential participants. They will provide potential partic-
ipants with trial information at one of three time points, 
that is, when potential participants (i) attend the service 
and are diagnosed with chlamydia, gonorrhoea or NSU; 
(ii) receive positive test results for chlamydia or gonor-
rhoea by phone or (iii) collect treatment for chlamydia, 
gonorrhoea or NSU from services.
Research staff will provide potential participants with 
verbal and written information (online supplementary file 
1) about the trial and/or participants will view trial infor-
mation on the website. Participants will be able to join 
the trial by either providing informed written consent to 
the research staff, or by providing consent online (online 
supplementary file 2) at the trial website or site staff can ask 
eligible participants if they are happy for their details to be 
given to research assistants based at the London School of 
Hygiene & Tropical Medicine Clinical Trials Unit (LSHTM 
CTU). In this case, LSHTM CTU will contact participants to 
recruit to the trial. Strategies for achieving adequate enrol-
ment include site visits, training, feedback and rewards, 
sharing successful recruiting strategies and newsletters.
Allocation and blinding
Participants will be randomly allocated (1:1 ratio), using 
a computer- based randomisation system, to a safer sex 
intervention delivered by text messaging, or to a control 
group, ensuring allocation concealment. Allocation 
concealment is ensured as the randomisation system is 
independent, automated and remote.
An electronic link to the computer- based randomi-
sation programme will result in the generation of a 
research number and allocation to the intervention or 
control group. The system will then automatically deliver 
intervention or control group texts according to the 
allocation.
Given the nature of the intervention, participants will 
be aware of their assigned group. Research assistants 
entering data, laboratory staff and researchers conducting 
the final analysis are masked to allocation until after the 
analysis is complete.
Interventions
Safetxt intervention group
The intervention aims to increase safer sex in three 
ways: (i) encouraging participants to correctly follow STI 
treatment instructions including informing partner(s) 
about infection, (ii) promoting condom use with new 
or casual partners and (iii) encouraging participants to 
obtain testing for STI prior to unprotected sex. Partic-
ipants in the intervention group will receive regular 
messages delivered by text message in community settings 
according to a predetermined schedule. The interven-
tion was informed by the capability, opportunity and 
motivation model of behaviour.28 It aims to influence the 
knowledge, beliefs, self- efficacy, skills, social and inter-
personal influences that have important effects on moti-
vation, capability and opportunity to reduce sexual risk 
behaviour.
Over the first 10 days participants are sent messages 
targeting engagement with the intervention, taking treat-
ment, avoiding sex for 7 days after treatment and telling 
partner(s) about an infection. These messages provide 
non- judgemental, non- stigmatising information about 
STI. They provide suggestions about when, where and 
how to tell partner(s) about an infection and examples 
of how others told partners covering a range of different 
types of relationship (eg, casual, long- term).
Messages then target condom use and testing for STIs 
before having sex without a condom with a new partner. 
Topics cover risk assessment, instructions on how to 
use condoms, positive aspects of condom use, tips on 
preventing condom problems and examples of how 
others resolved condom use problems. Participants are 
prompted to think about their own success in achieving 
safer sex strategies, risks they had taken and what they 
could do differently in the future. Messages included 
advice regarding testing before unprotected sex with 
a new partner. Participants are sent links to: services, 
support for those concerned about partner violence, 
and web- based information regarding contraception, 
alcohol and sexual risk, how to use a condom and general 
communication about sex. The messages provide social 
support for safer sex behaviours and acknowledge partic-
ipants experiences.
The intervention employs educational, enabling 
and incentivising behaviour change functions and 12 
behaviour change techniques: information about health 
consequences of behaviour, instruction on how to carry 
out the behaviour, demonstrations of risk reduction 
behaviour, social support, emotional support, social 
rewards, non- specific incentives, encouragement to add 
objects to the environment, anticipated regret, problem 
solving, action planning techniques and reframing.29 The 
information on safer sexual practices is in accordance 
with existing guidelines.
The messages are tailored according to gender and 
sexual orientation. Women who have sex with men only 
(WSM), men who have sex with men only (MSM), men 
who have sex with men and women (MSMW), women 
who have sex with men and women (WSMW) are sent 
messages about how others had negotiated condom use. 
WSM and men who have sex with women only (MSW) are 
sent messages about emergency contraception. MSM and 
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MSMW are sent messages about post exposure prophy-
laxis. Women who have sex with women only (WSW) are 
not sent messages about condom use. The information 
provided is specific to the STI diagnosed. This tailoring 
results in different numbers of messages being sent to 
those of different gender and sexual orientation.
The core message sets include: 74 messages for WSM 
and WSMW, 42 messages for WSW, 69 messages for MSW 
and 79 messages for MSMW and 76 messages for MSM. 
Recipients can request additional messages on specific 
topics. Participants are sent: four messages per day for 
days 1 to 3, then one to two messages per day for days 4 to 
28, then two to three messages per week for month 2 and 
two to five messages per month for months 3 to 12.
Control group
Participants in the control group will receive a monthly 
untailored text message asking for information about 
changes in postal or email addresses. Example control 
group message: ‘Thank you for taking part in the texting 
study. Remember to let us know if your contact details 
have changed by replying to this text or emailing  safetxt@ 
lshtm. ac. uk’.
All participants will receive usual care and will be free 
to seek any other existing service or support they wish. 
The control group is not attention matched as during the 
pilot work young people reported that it was irritating to 
receive the same number of messages as the intervention 
group about another health topic, when they had just 
been diagnosed with an STI. If the trial shows a benefit it 
is possible that this could be due to simply receiving the 
number of messages involved in the intervention, rather 
than the message content. However, given the lack of 
effect of some mobile phone message based interventions 
in sexual health this seems unlikely.14
All messages are sent automatically from a large data-
base to an aggregator, which conveys messages to each 
participant in the community via their network. The 
success of delivery of messages at each step is monitored 
by the aggregator and computer system that generates 
the messages. A member of the trial team will automat-
ically be notified if there is any failure in the delivery of 
messages. All participants will be able to set embargoed 
times when they do not want to receive messages. Partic-
ipants will be able to stop text messages, but continue 
with the trial follow- up, by texting ‘stop’ to the short code 
number.
outcomes
Our primary outcome will be the cumulative incidence of 
chlamydia and gonorrhoea infection at 1 year assessed by 
nucleic acid amplification tests: urine for men (with addi-
tional pharyngeal and anal swabs for MSM) and self- taken 
vulvovaginal swab for women.
secondary outcomes
Secondary outcomes at 4 weeks
Behaviours
 ► Whether participants took the (prescribed antibiotic) 
treatment and avoided sex for 7 days after treatment.
 ► Whether they told the last person they had sex 
with before testing positive, that they needed to get 
treatment.
 ► Clinic attendance by partner for treatment (identified 
from clinic records).
 ► Condom use at last sex.
Process outcomes – scores of the theoretical constructs 
underlying the components of the intervention 
(behaviour change mediators):
 ► Attitudes towards partner notification.
 ► Self- efficacy in telling a partner about an infection.
 ► Self- efficacy in negotiating condom use.
 ► Correct condom use self- efficacy.
 ► Knowledge related to STIs.
Secondary outcomes at 1 year
STIs
 ► Diagnosed with any STI after joining the trial 
according to self- report confirmed by postal test 
results and clinic records.
Behaviours
 ► Condom use at last sex.
 ► Number of sexual partners since joining the trial.
 ► Sex with someone new since joining the trial.
 ► Condom use at first sex with most recent new partner.
 ► Self- reported sexually transmitted infection testing for 
self - prior to first sex with most recent new partner.
 ► Sexually transmitted infection testing for self - prior 
to first sex with most recent new partner (confirmed 
according to clinic record that testing occurred).
 ► Participant’s report as to whether their most recent 
new partner was tested for sexually transmitted infec-
tion prior to sex with them.
 ► Number of sexual partners since joining the trial.
 ► Reading and sharing of intervention content.
 ► Number of text messages read.
 ► Whether anyone else read the messages, if yes how did 
the participant feel about them reading the messages?
 ► Reading someone else’s messages in the trial (to be 
reported for control group participants).
 ► Someone else in the trial reading participants’ 
messages (to be reported for intervention group 
participants).
Potential harms
 ► Car accident where the participant was the driver in 
the past year.30
 ► Experience of partner violence in the past year.31
data collection
The primary outcome will be assessed using chlamydia 
and gonorrhoea tests collected by post at 1 year and clinic 
records of completed tests. STI test kits for chlamydia and 
gonorrhoea will be posted (in P650 standard packaging) 
to respondents. Directions in the pack will ask partici-
pants to provide a vaginal swab (women), a urine sample 
(men) and additional anal and pharyngeal samples (men 
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Figure 2 Schedule of enrolment, interventions and 
assessments. NAAT,nucleic acid amplification test; STI, 
sexually transmitted infections.
who have sex with men) and post it in the prepaid and 
addressed envelope to the laboratory. Test kits will be 
identified by lab number only, rendering the laboratory 
staff blind to the participant’s allocation. The accredited 
laboratory will destroy samples after testing is completed.
Results of the STI testing will be reported on the secure 
trial lab site by lab code only. Clinical records will be 
checked to identify participants who have had a positive 
STI diagnosis since joining the study, confirm self- reported 
STI testing and partner attendance for treatment.
At 4 weeks and at 1 year, postal questionnaires will be 
sent to all participants to collect self- reported data. Non- 
responders will be contacted by any method the partic-
ipant agrees to at enrolment (post, email, text message, 
telephone call). Participants can directly enter self- 
reported outcome data via a web- based data entry form. 
Paper based self- reported outcome data or self- reported 
data collected by telephone will be directly entered into 
the web- based data entry form by a trial assistant blinded 
to treatment allocation.
Participants will be sent a £5 unconditional incentive 
with each postal request, that is, when sending the 4 
weeks questionnaire and 1 year test and questionnaire. 
Participants who return the test sample will be sent £20. 
See figure 2 for the Schedule of enrolment, interventions 
and assessments. All outcome data will be collected on 
participants who choose to stop messages unless they 
withdraw from the trial.
data management
Anonymised research data will be held on a secure system 
and password protected. All data systems will be set 
up with checks to alert the trial assistants if data being 
entered are illogical, inconsistent or incomplete.
Personal details will be stored on a password protected 
computer held on a secure server at the LSHTM. In accor-
dance with the Data Protection Act of 1998,32 this infor-
mation will be stored separately from any anonymised 
research data, and will be deleted at the end of the study.
Any paper- based data will be locked in a cabinet within 
a room. All trial procedures are in accordance with the 
principles of Good Clinical Practice. Essential documents 
of the sponsor/trial organisers and investigators will be 
retained for at least 10 years after completion of the trial.
sample size
The study is powered for the primary outcome measure 
of cumulative incidence of chlamydia and/or gonor-
rhoea infection at 1 year. Two main factors determine 
the number of participants needed for this trial: the esti-
mated event rate, and the size of the treatment effect. 
Our estimates are based on the following data:
Estimated event rate
The estimated event rate for the cumulative incidence of 
STI at 1 year is 20%, based on the event rate in cohort 
studies and the pilot trial.3
Size of treatment effect
Because the intervention can be administered to large 
populations at low cost, even a modest reduction in treat-
able STIs would be worthwhile. The trial has therefore 
been designed to detect a reduction in chlamydia or 
gonorrhoea infection of 20% versus 16% (relative risk 
0.8), which is similar to the effects of face- to- face safer sex 
interventions.7
Sample size calculation
In the pilot trial 2% of the control group viewed messages 
delivered to intervention participants. If the real differ-
ence in STI infection at 1 year follow- up is 20% versus 16% 
then with contamination of 2% the trial would detect a 
difference of 19.9% versus 16%. (Calculated based on 2% 
of the control group having an infection rate the same as 
the intervention group = (98% x 20%) + (2% x 16%) = 
19.9%).
Five thousand participants would provide 90% power 
to detect this difference, allowing for 20% losses to 
follow- up.
The Trial Steering Committee (TSC) reviewed the 
blinded event rate after 546 patients had completed 12 
months follow- up and recommended an increase in the 
sample size to 6250 due to a lower than expected event 
rate of 15.6%.
Analysis
A detailed statistical analysis plan (SAP) will be finalised 
and submitted to the TSC before the end of the trial and 
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unblinding. For the primary outcome and other binary 
outcomes, we will estimate any differences between the 
groups using logistic regression and we will report ORs 
with 95% CIs and p values, adjusting for key baseline 
predictors of outcome. These will be specified in advance 
in the SAP. For continuous outcomes, we will use linear 
regression to test for a difference in mean scores between 
the arms. All analyses will be based on the intention- to- 
treat principle.
For the primary analysis Multiple Imputation by Chained 
Equations (MICE) will be used in order to account for 
missing data.33 MICE makes appropriate assumptions for 
accommodating missing data in the analysis based on 
the predictors of outcome and the predictors of loss to 
follow- up. MICE is recognised as a way of reducing bias 
and increasing precision of trial results and is increasingly 
used as the primary analysis in randomised controlled 
trials.12 33 One hundred imputed data sets will be gener-
ated and the point estimates and SEs will be combined 
using Rubin’s rules. We will perform information- 
anchored sensitivity analysis using the delta- method.34
Supplementary analyses
Before fitting our primary analysis model, we need to 
identify appropriate auxiliary variables to include in the 
imputation model. Such auxiliary variables should have 
information about the missing outcome. Specifically, an 
independent statistician will use a data set without the 
treatment variable and perform regression analyses to 
identify key predictors of outcomes and which combina-
tion of baseline variables and time to negative STI test 
in clinic should be included as auxiliary variables in the 
imputation model. We will supplement this by performing 
and reporting a complete case analysis (where any partic-
ipants with missing information on any covariate or 
outcome shall be excluded).
Subgroup analyses
A limited number of subgroup analyses will be under-
taken adjusting for other key predictors of outcome. 
Subgroup analyses include: age,16–24 sexual orientation 
(men who have sex with men or men and women, men 
who have sex only with women, women who have sex with 
men or men and women, women who only have sex with 
women), ethnic group (Caucasian, Black, other) and age 
at which left education (16 or under, 17 or over). The 
subgroups will be analysed by inclusion of an interaction 
term between treatment group and the subgroup in the 
appropriate regression model for the outcome. Data will 
be presented by categories of subgroup using effect esti-
mates and 99% CIs. For each subgroup analysis, missing 
outcomes will be imputed consistent with the hypothesis 
of an interaction.35
Process outcomes
Candidate questionnaire items were identified for the 
measurement of the following constructs: attitudes 
towards partner notification, self- efficacy in telling a 
partner about an infection, self- efficacy in negotiating 
condom use, correct condom use self- efficacy, knowl-
edge related to STIs. At 4 weeks, each of the five process 
outcomes were measured using the candidate question-
naire items (three to five items per process outcome). 
Based on these items, we will carry out confirmatory 
factor analysis to refine and identify a valid measurement 
model. For the main trial analyses, the final measurement 
model will be combined with the intervention group 
allocation, along with key baseline predictors, extending 
the measurement model to a Multiple Causes Multiple 
Indicators model. This model will be used to estimate 
the effects of the intervention on the five hypothesised 
process outcomes.
Economic evaluation
The economic modelling required to assess the cost- 
effectiveness of the intervention will estimate the annual 
probability of members of the target group acquiring 
chlamydia, gonorrhoea and NSU with and without the 
intervention (based on the experience of those in the 
control and intervention arms of the trial). Detailed 
information will be collected on the costs of delivering 
the intervention. Secondary sources will be used to esti-
mate the future National Health Service (NHS) costs 
avoided as a consequence of avoided infections.
Patient involvement
Patients were involved in the development of the inter-
vention15 and the design of the trial materials and 
follow- up procedures.36 A patient is also a member of the 
Trial Steering Committee. Young people will be involved 
in the dissemination of the trial results.
Monitoring
The safetxt trial will not have a separate Data Moni-
toring Committee. No interim analyses of intervention 
effects will be conducted since the trial is of a behavioural 
support intervention unlikely to cause harm, and there-
fore, there are no stopping rules. Analysis of intervention 
effects will be conducted once at the end of the trial. The 
sponsor may audit the trial per their own risk assessment 
and schedule.
Harms will be assessed by self- reported data. Car acci-
dents are the only demonstrated harm resulting from text 
messaging, hence the intention to collect data regarding 
involvement in road traffic accidents. The safetxt inter-
vention aims to increase partner notification of STI 
status. Fear of partner violence has been reported to 
be a barrier to partner notification and partner notifi-
cation has been identified as a factor which may trigger 
partner violence. However, no randomised controlled 
trials targeting increased partner notification detected a 
difference in partner violence between the control inter-
vention groups. Data will be collected regarding the expe-
rience of partner violence at 12 months.
In addition, participants will be asked an open- ended 
question in the 12- month questionnaire: ‘Did anything 
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good or bad happen as a result of being involved in the 
study or receiving the text messages? Please describe.’ 
The Clinical Trials Unit will keep detailed records of all 
adverse events reported. Reports will be reviewed by the 
Principal Investigator and the TSC to consider intensity, 
causality and expectedness. As appropriate, these will be 
reported to the sponsor and the Ethics Committee.
Ethics and dissemination
All trial participants will provide written informed consent 
prior to enrolment in the trial. Participants’ can withdraw 
from the trial on request. Participant will receive usual 
NHS care there is no ancillary care.
Any modifications to the protocol will be approved by 
the ethics committee prior to implementation. Records 
of any important modifications will be submitted as 
an addendum in the journal in which this protocol is 
published.
Trial results will be published open- access in peer- review 
journals. Authorship will be on the basis of meeting the 
criteria recommended by the International Committee of 
Medical Journal Editors.
After the publication of our main trial findings, the 
anonymised trial data set will be available on request from 
the corresponding author.
dIsCussIon
STIs such as chlamydia and gonorrhoea confer a heavy 
burden of disease among young people with long- term 
sequelae such as infertility. Safer sex behaviours such as 
condom use, notifying partner(s) about an existing STI 
and STI testing reduce the risk of STI, but young people 
may lack the knowledge, confidence and skills needed to 
adopt these behaviours. Safer sex interventions delivered 
by mobile phone are acceptable to young people and 
show promise in increasing safer sex behaviours, but to 
date their effects on STI are not reliably known.
If it proves to be effective, this low- cost intervention 
could have an important impact in improving sexual 
health and reducing inequalities among young people 
in the UK. There is likely to be international interest in 
the impact of the intervention as short written messages 
delivered via mobile phones are increasingly used for 
behavioural support worldwide and sexually transmitted 
infections remain an important cause of morbidity and 
mortality.
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